These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30921804)

  • 21. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR; Stumpf JL
    Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study.
    Suratannon N; Limsuwan T; Tantilipikorn P; Chatchatee P; Saengapaswiriya A; Boonpiyathad T; Thongngarm T; Roongpuvapaht B; Chantaphakul H; Kulalert P; Thanaviratananich S; Sangsupawanich P; Fooanant S; Manuyakorn W; Chusakul S; Piboonpochanun O; Apornpong T; Wongpiyabovorn J; Ruxrungtham K;
    Asian Pac J Allergy Immunol; 2024 Sep; 42(3):233-245. PubMed ID: 39417769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
    Hesse L; Nawijn MC
    Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy.
    Feng M; Su Q; Lai X; Xian M; Shi X; Wurtzen PA; Qin R; Zeng X; Li J
    J Immunol; 2018 Jun; 200(12):3897-3904. PubMed ID: 29728509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children.
    Rosewich M; Arendt S; El Moussaoui S; Schulze J; Schubert R; Zielen S
    Pediatr Allergy Immunol; 2013 Aug; 24(5):434-40. PubMed ID: 23578317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
    Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
    J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
    Liu Y; Xing Z; Wang J; Geng C
    Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients.
    Pfaar O; Nell MJ; Boot JD; Versteeg SA; van Ree R; Roger A; Riechelmann H; Sperl A; Oude Elberink JN; Diamant Z; Bachert C
    Allergy; 2016 Jul; 71(7):967-76. PubMed ID: 26864207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
    Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
    Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the Allergenic Potency of House Dust Extract and House Dust Mite Allergen Extract for Subcutaneous Allergen Immunotherapy.
    Du W; Fukano C; Yonemoto M; Matsuoka T; Masuyama K; Ohashi-Doi K
    Biol Pharm Bull; 2019; 42(4):601-606. PubMed ID: 30930419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
    Eifan AO; Calderon MA; Durham SR
    Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.
    O'Hehir RE; Gardner LM; de Leon MP; Hales BJ; Biondo M; Douglass JA; Rolland JM; Sandrini A
    Am J Respir Crit Care Med; 2009 Nov; 180(10):936-47. PubMed ID: 19696440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
    Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
    Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model.
    Hesse L; van Ieperen N; Habraken C; Petersen AH; Korn S; Smilda T; Goedewaagen B; Ruiters MH; van der Graaf AC; Nawijn MC
    Allergy; 2018 Apr; 73(4):862-874. PubMed ID: 29318623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
    J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis.
    Nahm DH; Kim ME; Kwon B; Cho SM; Ahn A
    Yonsei Med J; 2016 Nov; 57(6):1420-6. PubMed ID: 27593870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy.
    Boonpiyathad T; Sokolowska M; Morita H; Rückert B; Kast JI; Wawrzyniak M; Sangasapaviliya A; Pradubpongsa P; Fuengthong R; Thantiworasit P; Sirivichayakul S; Kwok WW; Ruxrungtham K; Akdis M; Akdis CA
    Allergy; 2019 May; 74(5):976-985. PubMed ID: 30485456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.